Polymersome delivery of siRNA and antisense oligonucleotides

被引:131
|
作者
Kim, Younghoon [1 ,2 ]
Tewari, Manorama [1 ,2 ]
Pajerowski, J. David [1 ,2 ]
Cai, Shenshen [1 ,2 ]
Sen, Shamik [1 ,2 ]
Williams, Jason [3 ]
Sirsi, Shashank [3 ]
Lutz, Gordon [3 ]
Discher, Dennis E. [1 ,2 ]
机构
[1] Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA
[2] Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA
[3] Drexel Univ, Coll Med, Dept Pharmacol, Philadelphia, PA 19104 USA
关键词
Polymersome; siRNA; AON; Antisense; Exon skipping; Muscular dystrophy; RESTORES DYSTROPHIN EXPRESSION; DUCHENNE MUSCULAR-DYSTROPHY; IN-VIVO; SYSTEMIC DELIVERY; MOLECULAR-WEIGHT; MUSCLE-CELLS; MDX MOUSE; EXON; VESICLES; RELEASE;
D O I
10.1016/j.jconrel.2008.10.020
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
siRNA and antisense oligonucleotides, AON, have similar size and negative charge and are often packaged for in vitro delivery with cationic lipids or polymers-but exposed positive charge is problematic in vivo. Here we demonstrate loading and functional delivery of RNAi and AON with non-ionic, nano-transforming polymersomes. These degradable carriers are taken up passively by cultured cells after which the vesicles transform into micelles that allow endolysosomal escape and delivery of either siRNA into cytosol for mRNA knockdown or else AON into the nucleus for exon skipping within pre-mRNA. Polymersome-mediated knockdown appears as efficient as common cationic-lipid transfection and about half as effective as Lentivirus after sustained selection. For AON, initial results also show that intramuscular injection into a mouse model of muscular dystrophy leads to the expected protein expression, which occurs along the entire length of muscle. The lack of cationic groups in antisense polymersomes together with initial tests of efficacy suggests broader utility of these non-viral carriers. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:132 / 140
页数:9
相关论文
共 50 条
  • [31] Topical and transdermal delivery of antisense oligonucleotides
    Brand, RM
    [J]. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2001, 3 (03) : 244 - 248
  • [32] Oral delivery of antisense oligonucleotides in man
    Tillman, Lloyd G.
    Geary, Richard S.
    Hardee, Gregory E.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (01) : 225 - 236
  • [33] Targeted delivery of antisense oligonucleotides in cancer
    Pastorino, F
    Stuart, D
    Ponzoni, M
    Allen, TM
    [J]. JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) : 69 - 75
  • [34] Innovative nanotechnologies for the delivery of oligonucleotides and siRNA
    Toub, N.
    Malvy, C.
    Fattal, E.
    Couvreur, P.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2006, 60 (09) : 607 - 620
  • [35] Nanoparticulate systems for the delivery of antisense oligonucleotides
    Lambert, G
    Fattal, E
    Couvreur, P
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (01) : 99 - 112
  • [36] Aspects of the transport and delivery of antisense oligonucleotides
    Juliano, RL
    Yoo, H
    [J]. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2000, 2 (03) : 297 - 303
  • [37] Development of delivery systems for antisense oligonucleotides
    Takakura, Y
    Mahato, RI
    Nomura, T
    Sawai, K
    Yoshida, M
    Kanamaru, T
    Hashida, M
    [J]. ADVANCED BIOMATERIALS IN BIOMEDICAL ENGINEERING AND DRUG DELIVERY SYSTEMS, 1996, : 357 - 358
  • [39] Antisense Pharmacodynamics: Critical Issues in the Transport and Delivery of Antisense Oligonucleotides
    R. L. Juliano
    S. Alahari
    H. Yoo
    R. Kole
    M. Cho
    [J]. Pharmaceutical Research, 1999, 16 : 494 - 502
  • [40] Antisense pharmacodynamics: Critical issues in the transport and delivery of antisense oligonucleotides
    Juliano, RL
    Alahari, S
    Yoo, H
    Kole, R
    Cho, M
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (04) : 494 - 502